Aoxin Q & M Dental Group Limited: FY2025 Financial Analysis and Outlook

Aoxin Q & M Dental Group Limited, listed on the Catalist Board of SGX, has released its condensed interim financial statements for the year ended 31 December 2025. The Group operates in primary healthcare (dentistry), distribution of dental equipment and supplies, and laboratory services. Below is a structured review of key financial metrics, performance trends, corporate actions, and outlook based entirely on the company’s official disclosures.

Key Financial Metrics and Comparisons

Historical Performance Trends

• FY2025 revenue declined 3.6% YoY to RMB171.0 million, mainly due to weaker consumer sentiment in China and lower average revenue per patient in the primary healthcare segment.
• Net profit rebounded to RMB6.9 million in FY2025 from a loss of RMB8.0 million in FY2024, driven by improved expense control and the absence of large associate losses.
• EPS turned positive at 1.30 RMB cents for FY2025 (vs. -1.56 in FY2024).

Segment Performance

• Primary healthcare segment revenue fell 8.8% YoY, reflecting macro headwinds and cautious consumer spending.
• Distribution of dental equipment and supplies grew 6.0% YoY, aided by sales to government hospitals.
• Laboratory services rose 4.6% YoY, driven by expansion in Singapore.

Exceptional Items and Restatements

• A RMB6.2 million overclaim in FY2024 was identified and rectified, resulting in a restatement of prior period revenue, losses, and liabilities. The overclaim was fully repaid to NHSA in FY2025.
• Associate losses sharply reduced (from RMB14.2 million in FY2024 to RMB0.03 million in FY2025) after asset impairments and the cessation of Covid-19 contracts in prior periods.
• Other losses increased (RMB2.7 million vs RMB0.8 million in FY2024) due to impairment of non-trade receivables, bad debt write-offs, legal compensation, and FX losses.

Fundraising and Capital Actions

• A substantial rights issue completed in Q4 2025 raised net proceeds of S\$15.0 million (RMB82.8 million), doubling the share count to 1,023,044,096 shares.
• Proceeds remain unutilized as at year end, earmarked for business expansion, asset investment, and working capital.
• Share awards were granted to high-performing employees (20 million shares), enhancing employee retention.

Cash Flow and Balance Sheet

• Cash and cash equivalents surged to RMB148.7 million (from RMB69.9 million), mainly due to fundraising.
• Operating cash flow was positive but modest (RMB4.1 million for FY2025), reflecting tighter margins and slower collections.
• Net asset value per share declined due to share dilution and restated losses.

Events, Risks and Outlook

• Regulatory scrutiny and compliance requirements have intensified, particularly regarding medical insurance fund usage and documentation.
• Centralized volume-based procurement for dental implants remains a headwind for margins.
• Management aims to mitigate through cost controls, digital dentistry, and AI adoption.
• Expansion into Singapore and Southeast Asia is underway, targeting growth in laboratory services.
• Asset rationalization continues, with some subsidiaries struck off and a new joint venture established for lab services.

Chairman’s Statement

“The dental services industry in China is undergoing a period of consolidation, driven by intensified competition, pricing pressures from centralised procurement policies, rising operating costs and stricter regulatory oversight. These factors have placed financial strain on certain smaller dental operators, creating selective acquisition opportunities for the Group. The Group intends to deploy the RMB43.7 million (or S\$8.0 million) expansion allocation to pursue acquisition opportunities, particularly targeting established dental clinic chains outside North-Eastern China, where the Group currently operates. … Overall, notwithstanding regulatory and pricing headwinds, the Board is optimistic that the Group is well positioned to navigate industry changes and capture sustainable growth opportunities through disciplined management, clinical excellence and operational scale.”

Tone: Cautiously optimistic, with recognition of significant challenges but confidence in long-term growth potential.

Dividends

• No dividend declared for FY2025 or FY2024. Management is conserving cash for working capital and expansion.

Related Party Transactions

• Related party revenue from laboratory services: S\$716,000.
• Related party expenses: S\$156,000.
• No outstanding share options or convertible instruments as at year-end.

Conclusion and Investment Recommendations

Overall Assessment: The Group’s performance has recovered from prior losses, with positive net profit and EPS in FY2025. However, revenue remains under pressure due to macroeconomic and regulatory headwinds, and net asset value per share has declined following a substantial rights issue. Cash reserves are strong, and management is positioned to pursue growth opportunities, especially through M&A and regional expansion.

• If you are currently holding the stock: Consider holding your position. The Group has returned to profitability, has strengthened its balance sheet, and is poised for strategic expansion. However, monitor regulatory risk, margin pressure, and asset utilization of the proceeds from the rights issue.
• If you are not currently holding the stock: Exercise caution. While the turnaround and cash position are positives, revenue growth is weak and sector risks remain elevated. Wait for evidence of successful deployment of funds and tangible growth in new regions before entering.

Disclaimer: This analysis is based solely on company-reported financials and does not constitute investment advice. Investors should conduct their own due diligence and consider their risk tolerance and financial objectives before making investment decisions.

View Aoxin Q & M Historical chart here